SFSusan C. Fagan

Susan C. Fagan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susan C. Fagan has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Adviye Ergul

    Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia and Charlie Norwood, VA Medical Center (A.A., A.K., A.E., S.C.F.), and Departments of Physiology (A.E.) and Neurology (S.C.F.), Georgia Health Sciences University, Augusta, Georgia

    5 shared publications
  • Adviye Ergul

    Medical University of South Carolina

    5 shared publications
  • Ahmed Alhusban

    University of Sharjah

    3 shared publications
  • Anna Kozak

    Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia and Charlie Norwood, VA Medical Center (A.A., A.K., A.E., S.C.F.), and Departments of Physiology (A.E.) and Neurology (S.C.F.), Georgia Health Sciences University, Augusta, Georgia

    3 shared publications
  • Weihua Guan

    Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, Augusta, GA

    3 shared publications
  • Bindu Pillai

    Univ of Georgia, College of Pharmacy, Augusta, GA

    2 shared publications

Latest Publications

  • Abstract WP109: Deferoxamine Improves Vascular Repair and Cognitive Outcomes After Embolic Stroke In Diabetic but Not Control Animals: Interaction With tPA

    by Weiguo Li, Guangkuo Dong, Paul T Menk, Yasir Abdul, Rebecca Ward, Susan C Fagan, Adviye Ergul

    Diabetes increases the risk of hemorrhagic transformation (HT) in ischemic stroke, especially with the use of tissue plasminogen activator (tPA). We showed that iron chelation therapy with deferoxamine (DFX) improves functional outcome in male diabetic animals after embolic stroke but its interaction with tPA remained unknown. We also reported that increased HT is associated with loss of cerebrovasculature in the recovery period in diabetic animals. This study tested the hypotheses that DFX treatment initiated after stroke 1) will improve neurological recovery after embolic stroke with tPA, and 2) will prevent cerebrovascular regression in diabetes. Control and type 2 diabetic animals were subjected to embolic middle cerebral artery occlusion. tPA (1 mg/kg) was given at 90 min post-occlusion. DFX (100 mg/kg) or vehicle was given every 12 h for 7 days after stroke. The composite score (Bederson’s score and beam walk), adhesive removal (ART) and novel object recognition (NOR) were assessed at day 3, 7 and 14 after the surgery. Cerebrovascularization indices in the ipsilateral cortex (vascular volume, surface area, and branch density) were measured with 3D imaging. DFX improved sensorimotor deficits in both groups and this effect was more robust in tPA combination. While DFX lowered vascularization indices in control animals, it prevented vasoregression in diabetes. Interestingly, DFX prevented the recovery of cognitive function in controls while improving it in diabetic animals. These results suggest that treatment with DFX may improve long term recovery in diabetes.

  • Abstract TP88: Delayed Therapeutic Window for Prevention of Progressive Cognitive Impairment After Experimental Stroke

    by Heba A Ahmed, Tauheed Ishrat, Bindu Pillai, Abdelrahman Y Fouda, Mohammed A Sayed, Jennifer L Waller, Adviye Ergul, Susan C Fagan

    Background: With the aging population, the prevalence and incidence of cerebrovascular disease will continue to rise, as will the number of individuals with post-stroke cognitive impairment (PSCI). Unfortunately, no specific FDA approved treatments for PSCI exist. Although clinical trial evidence supports that renin angiotensin system (RAS) modulation by angiotensin receptor blockers (ARBs) prevent cognitive decline in older adults. The aim of our study was to determine the impact of the ARB candesartan or the AT2R agonist, C21, after stroke, on long-term cognitive function in spontaneously hypertensive rats (SHRs). Methods: Thirty three SHRs were subjected to a 60 minute transient middle cerebral artery occlusion (MCAO) and randomly assigned to either Saline/ C21 (0.3 mg/kg, IP) only or Saline/ C21 (7 days) followed by candesartan (0.3 mg/kg) IP for the remainder of the study. Outcome measures included sensorimotor and cognitive function, performed using a sequence of blinded tests, and assessed at baseline and up to 28 days post-stroke. Animals were sacrificed at 30 days and their brains collected for amyloid-β protein determination and histopathologic analyses. Results: Chronic administration of C21, or candesartan prevented PSCI, even when treatment was initiated at 7 days after the ischemic insult. The groups treated with C21 and candesartan demonstrated superior performance on the novel NOR test, compared to saline treated animals. C21 (first 7 days) only or C2 and candesartan treatments had markedly lower hippocampal concentrations of Aβ1-42 at 30 days post-stroke than those treated with saline. Sensorimotor deficits (Bederson and beam walk scores) were pronounced at 24 h post-stroke and all treatment groups showed similar recovery at 28 days post stroke. C21 had no effect on BP compared to saline-treated controls. Conclusion: Collectively, our findings demonstrate that RAS modulators effectively prevent PSCI, even when treatment is delayed.

  • Abstract TP89: Angiotensin Receptor (AT2R) Agonist C21 Accelerates Cognitive Functional Recovery After Permanent Stroke in Aged Animals

    by Heba A Ahmad, Tauheed Ishrat, Bindu Pillai, Kristopher Bunting, Almira Vazdarjanova, Jennifer L Waller, Adviye Ergul, Susan C Fagan

    Background and objectives: Post stroke cognitive impairment (PSCI) is an understudied, long-term complication of stroke, impacting nearly 30-40% of all stroke survivors. No cure is available once the cognitive deterioration manifests. Compound 21 (C21), a novel selective non-peptide angiotensin receptor (AT2R) agonist, has also shown therapeutic efficacy in a variety of experimental stroke models, but C21 effect on PSCI model is lacking. To our knowledge, this is the first study to investigate the long-term effects of C21 treatment on the development of PSCI in aged animals. Methods: Distal docal cerebral ischemia was induced in 14-month-old male Wistar rats by direct electro-coagulation of middle cerebral artery for permanent occlusion (pMCAO). Animals were randomly assigned to receive either C21 or vehicle which was initiated the following day, and continued for a total of 30 days (0.12 mg/kg/d, orally). Outcome measures for sensorimotor and cognitive function were performed using a sequence of tests, all blindly conducted and assessed at baseline as well as at different time points post-pMCAO. Repeated measures ANOVA mixed models were used to examine differences in behavioral outcomes. Results: C21 reduced weight loss and enhanced recovery (Table). Treatment with C21 showed significant improvement in non-spatial and short-term working memory compared to vehicle. Moreover, C21 preserved reference memory and facilitated associative learning compared to vehicle treated rats after pMCAO. Further, C21 prevented Aβ 1-42 . C21 did not show any effect on motor deficits score compared to vehicle. Conclusion: Our findings demonstrate that the angiotensin receptor (AT2R) agonist C21 effectively preserves cognitive function and prevents the development of PSCI in aged animals.

  • Abstract TP112: Differential Effects of Deferoxamine Treatment on Neurological Deficits in Young Diabetic Female Animals After Embolic Stroke

    by Weiguo Li, Guangkuo Dong, Paul T Menk, Yasir Abdul, Rebecca Ward, Susan C Fagan, Adviye Ergul

    Premenopausal women have lower stroke risk and mortality than age-matched men, a finding replicated in preclinical models. However, we recently reported that female diabetic rats developed greater hemorrhagic transformation (HT) after embolic stroke and thrombolysis with tPA, leading to poor short term outcomes, despite no change in infarct size. Given that iron chelation therapy with deferoxamine (DFX) in the recovery period improves long term functional outcome in male diabetic rats that develop HT after embolic stroke, the current study tested the hypothesis that DFX will improve neurological recovery in diabetic females, especially with tPA combined treatment. Control and type 2 diabetic female animals were subjected to embolic middle cerebral artery occlusion. DFX (100 mg/kg) or vehicle was given every 12 h for 7 days after stroke. tPA (1 mg/kg) was given at 90 min post-occlusion to diabetes group. The composite score (Bederson’s score and beam walk), adhesive removal (ART) and novel object recognition (NOR) were assessed at day 3, 7 and 14 after the surgery. DFX improved sensorimotor deficits in both groups, and the combination with tPA in the diabetes group had a similar effect to DFX alone. Control vehicle group regained cognitive function but there was no change in diabetic animals which had deficits at baseline. Interestingly, cognitive deficits increased in the control DFX and diabetes tPA+DFX group. These results suggest that DFX treatment may improve the long term sensorimotor deficits in diabetic females after stroke but the impact on cognitive outcomes needs further evaluation.

  • AT1 Receptor Antagonism Is Proangiogenic in the Brain: BDNF a Novel Mediator

    by Ahmed Alhusban, Anna Kozak, Adviye Ergul, Susan C. Fagan

    Candesartan is an angiotensin II type 1 receptor blocker (ARB) that has been to shown to limit ischemic stroke and improve stroke outcome. In experimental stroke, candesartan induces a proangiogenic effect that is partly attributable to vascular endothelial growth factor. Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family that has been reported to have angiogenic effects and play an important role in recovery after stroke. The purpose of this investigation was to determine the role of BDNF in the proangiogenic effect of candesartan in the brain under hypertensive conditions. Accordingly, spontaneously hypertensive rats were treated with candesartan, and brain tissue samples were collected for quantification of BDNF expression. In addition, human cerebromicrovascular endothelial cells were treated with either low-dose (1 ƒM) or high-dose (1 µM) angiotensin II alone or in combination with candesartan (0.16 µM) to assess the effect of candesartan treatment and BDNF involvement in the behavior of endothelial cells. Candesartan significantly increased the expression of BDNF in the SHR (P < 0.05). In addition, candesartan reversed the antiangiogenic effect of the 1-µM dose of AngII (P = 0.0001). The observed effects of candesartan were ablated by neutralizing the effects of BDNF. Treatment with the AT2 antagonist PD-123319 significantly reduced tube-like formation in endothelial cells. AT2 stimulation induced the BDNF expression and migration (P < 0.05). In conclusion, candesartan exerts a proangiogenic effect on brain microvascular endothelial cells treated with angiotensin II. This response is attributable to increased BDNF expression and is mediated through stimulation of the AT2 receptor.


  • Recommendations for Preclinical Research in Hemorrhagic Transformation

    by Susan C. Fagan, Paul A. Lapchak, David S. Liebeskind, Tauheed Ishrat, Adviye Ergul

    Hemorrhagic transformation (HT) is an important complication of ischemic stroke and is responsible for most of the mortality associated with acute reperfusion therapy. Although many important publications address the preclinical models of ischemic stroke, there are no current recommendations on the conduct of research aimed at understanding the mechanisms and consequences of HT. The purpose of this review is to present the various models used in HT research, the clinical correlates, and the experimental variables known to influence the quantitation of HT in preclinical investigation. Lastly, recommendations for the conduct of preclinical research in HT are provided.


  • Angiogenesis

    by Adviye Ergul, Ahmed Alhusban, Susan C. Fagan


  • Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke

    by Tauheed Ishrat, Sahar Soliman, Weihua Guan, Mihaela Saler, Susan C. Fagan

    Thrombolytic therapy with tissue plasminogen activator (tPA) remains the most effective treatment for acute ischemic stroke, but can cause vascular damage leading to edema formation and hemorrhagic transformation (HT). In this review, we discuss how tPA contributes to the pathogenesis of vascular damage and highlight evidence to support combination therapy of tPA with pharmacological agents that are vascular protective. There is an unmet need to develop therapeutic interventions which target the underlying mechanisms of vascular damage after acute ischemic stroke in order to prevent HT and improve the safety and impact of tPA.


  • Cerebrovascular Complications of Diabetes: Focus on Stroke

    by Adviye Ergul, Aisha Kelly-Cobbs, Maha Abdalla, Susan C. Fagan

    Cerebrovascular complications make diabetic patients 2-6 times more susceptible to a stroke event and this risk is magnified in younger individuals and in patients with hypertension and complications in other vascular beds. In addition, when patients with diabetes and hyperglycemia experience an acute ischemic stroke they are more likely to die or be severely disabled and less likely to benefit from the one FDA-approved therapy, intravenous tissue plasminogen activator. Experimental stroke models have revealed that chronic hyperglycemia leads to deficits in cerebrovascular structure and function that may explain some of the clinical observations. Increased edema, neovascularization and protease expression as well as altered vascular reactivity and tone may be involved and point to potential therapeutic targets. Further study is needed to fully understand this complex disease state and the breadth of its manifestation in the cerebrovasculature.


  • Treatment of Fever After Stroke: Conflicting Evidence

    by Sylwia E. Wrotek, Wieslaw E. Kozak, David C. Hess, Susan C. Fagan

    Approximately 50% of patients hospitalized for stroke develop fever. In fact, experimental evidence suggests that high body temperature is significantly correlated to initial stroke severity, lesion size, mortality, and neurologic outcome. Fever occurring after stroke is associated with poor outcomes. We investigated the etiology of fever after stroke and present evidence evaluating the efficacy and safety of interventions used to treat stroke‐associated fever. Oral antipyretics are only marginally effective in lowering elevated body temperature in this population and may have unintended adverse consequences. Nonpharmacologic approaches to cooling have been more effective in achieving normothermia, but whether stroke outcomes can be improved remains unclear. We recommend using body temperature as a biomarker and a catalyst for aggressive investigation for an infectious etiology. Care must be taken not to exceed the new standard of a maximum acetaminophen dose of 3 g/day to avoid patient harm.